Industry
Biotechnology
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 3:20 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 9:57 pm
Portfolio Pulse from Benzinga Newsdesk
May 13, 2024 | 3:39 pm
Portfolio Pulse from Benzinga Newsdesk
May 13, 2024 | 12:40 pm
Portfolio Pulse from Benzinga Newsdesk
May 10, 2024 | 1:49 pm
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 9:00 pm
Portfolio Pulse from Benzinga Newsdesk
April 23, 2024 | 5:24 pm
Portfolio Pulse from Benzinga Insights
April 05, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
March 22, 2024 | 5:13 pm
Portfolio Pulse from Benzinga Newsdesk
March 21, 2024 | 1:39 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.